<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Propiverine (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Propiverine (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Propiverine (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="111933" href="/d/html/111933.html" rel="external">see "Propiverine (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871695"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Mictoryl;</li>
<li>Mictoryl Pediatric</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26343122"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F26343124"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Overactive bladder:</b>
<b>Oral:</b> Modified release<i>: </i>Initial: 30 mg once daily; may increase to a maximum of 45 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991333"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No dosage adjustment necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Maximum dose: 30 mg/day.</p></div>
<div class="block doha drugH1Div" id="F50988701"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: No dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment: Use is contraindicated.</p></div>
<div class="block dop drugH1Div" id="F50405199"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b> Children and Adolescents: Oral: Immediate release: 0.8 mg/kg/day in 2 divided doses or alternatively the following body weight adjusted dosing may be used:</p>
<p style="text-indent:-2em;margin-left:4em;">12 to 16 kg: 5 mg two times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">17 to 22 kg: 5 mg in the morning and 10 mg in the evening.</p>
<p style="text-indent:-2em;margin-left:4em;">23 to 28 kg: 10 mg two times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">29 to 34 kg: 10 mg in the morning and 15 mg in the evening.</p>
<p style="text-indent:-2em;margin-left:4em;">≥35 kg: 15 mg two times daily (maximum: 30 mg/day).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note</b>: Modified-release capsules should not be used in pediatric patients.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F26619254"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Fatigue (≥0.1% to &lt;5%), hypotension (0.1% to &lt;5%), edema (&gt;0.1%), hypertension (&gt;0.1%), palpitation (&gt; 0.1%), atrioventricular block, bradycardia, chest pain, extrasystoles, flushing, prolonged QT interval on ECG, tachycardia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Dizziness (0.1% to &lt;5%), fatigue (0.1% to &lt;5%), headache (0.1% to &lt;5%), drowsiness (&lt;0.1%), excitability (&gt;0.1%), insomnia (&gt;0.1%), paralysis (&gt;0.1%), confusion, delirium, hallucination, impaired consciousness, restlessness</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Pruritus (0.1% to &lt;5%), skin rash (0.1% to &lt;5%), urticaria (&gt;0.1%), erythema, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Polydipsia (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain (0.1% to &lt;5%), constipation (0.1% to &lt;5%), dyspepsia (0.1% to &lt;5%), diarrhea (0.1% to &lt;5%), nausea (0.1% to &lt;5%), vomiting (0.1% to &lt;5%), xerostomia (≥1%), anorexia (&gt;0.1%), cleft palate (&gt;0.1%), dysgeusia (&lt;0.1%), glossitis (&gt;0.1%), stomatitis (&gt;0.1%), abdominal distension, intestinal obstruction, sore throat</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Dysuria (0.1% to &lt;5%), increased post-void residual urine (0.1% to &lt;5%), urinary incontinence (&gt;0.1%), urinary retention (&lt;0.1%), anuria</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Leukopenia (0.1% to &lt;5%), myoglobin increased, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Increased serum alkaline phosphatase (0.1% to &lt;5%), increased serum transaminases (0.1% to &lt;5%), hepatic insufficiency, jaundice</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Back pain (&gt;0.1%), tremor (&gt;0.1%), weakness (&gt;0.1%), dyskinesia, increased creatine phosphokinase, myalgia, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Oculomotor disturbance (0.1% to &lt;5%), accommodation disturbances (&lt;1%), visual disturbance (&lt;1%), dry eye syndrome (0.1%), eye pain, glaucoma, increased intraocular pressure</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Increased blood urea nitrogen (&gt;0.1%), increased creatinine clearance (&gt;0.1%), renal insufficiency</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Increased bronchial secretions (&gt;0.1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever (&gt;0.1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing, and/or case reports: Cough, dyschromia, leukocytosis, pain, reduced urine flow, tinnitus, upper respiratory tract infection</p></div>
<div class="block coi drugH1Div" id="F26619253"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to propiverine or any component of the formulation; gastrointestinal obstructive disorder; angle-closure glaucoma (uncontrolled); intestinal atony; myasthenia gravis; tachyarrhythmias; toxic megacolon; severe ulcerative colitis; moderate or severe hepatic impairment; significant degree of bladder outflow obstruction where urinary retention may be anticipated; rare hereditary problems of galactose intolerance, glucose-galactose malabsorption, or congenital lactase deficiency; children with rare hereditary problems of fructose intolerance or sucrose-isomaltase insufficiency.</p></div>
<div class="block war drugH1Div" id="F45807245"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness and blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure, tachycardia, and/or cardiac arrhythmias; may exacerbate condition. Use is contraindicated in patients with tachyarrhythmias. Monitor patients at risk for QTc prolongation during therapy (have not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; may exacerbate condition. Use is contraindicated in patients with uncontrolled angle-closure glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild hepatic impairment. Monitor hepatic function closely and discontinue if transaminases and/or bilirubin are above normal limits. Use is contraindicated in patients with moderate or severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Use with caution in patients with autonomic neuropathy; may aggravate symptoms of decreased GI motility</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture; may cause urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be required in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Prior to initiating therapy, rule out alternative causes of pollakiuria and nocturia (eg, organic bladder disease such as UTI or malignancy, heart failure).</p></div>
<div class="block prod-avail drugH1Div" id="F22786054"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040767"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52871696"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mictoryl: 30 mg, 45 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mictoryl Pediatric: 5 mg</p></div>
<div class="block adm drugH1Div" id="F45807263"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IR tablets: Administer at least 1 hour before meals particularly in patients with renal/mild hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Modified-release capsules: May administer without respect to meals. Do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Capsule, modified release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER capsules should be swallowed whole. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block admp drugH1Div" id="F52618134"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Immediate-release tablets: Administer at least 1 hour before meals particularly in patients with renal/mild hepatic impairment.</p></div>
<div class="block use drugH1Div" id="F26343123"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in US.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b> Treatment of symptoms (incontinence, frequency, urgency) due to overactive bladder</p></div>
<div class="block mst drugH1Div" id="F53727071"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Based on pharmacologic class concerns for anticholinergics in the Beers Criteria, propiverine may be a potentially inappropriate medication to be avoided in patients ≥65 years due to its anticholinergic properties (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45839460"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F45839457"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: Propiverine may enhance the adverse/toxic effect of Amantadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lemborexant.  Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lonafarnib.  Management: Avoid concurrent use of lonafarnib with weak CYP3A4 inhibitors. If concurrent use is unavoidable, reduce the lonafarnib dose to or continue at a dose of 115 mg/square meter. Monitor for evidence of arrhythmia, syncope, palpitations, or similar effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of Simvastatin. CYP3A4 Inhibitors (Weak) may increase the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a weak CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Ubrogepant.  Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F45807243"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been reported in animal reproduction studies. Use is not recommended in pregnancy.</p></div>
<div class="block brc drugH1Div" id="F45807244"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if propiverine is present in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F45807264"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Hepatic function during long-term therapy; renal function; intraocular pressure in patients at risk of developing glaucoma; QTc interval (patients at risk for QTc prolongation)</p></div>
<div class="block pha drugH1Div" id="F45807248"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Propiverine and three active metabolites account for pharmacologic effects; antispasmodic effect by inhibiting calcium influx and modulating intracellular calcium in bladder smooth muscle; also has anticholinergic activity leading to decreased intravesical pressure.</p></div>
<div class="block phk drugH1Div" id="F45807249"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Nearly complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Mean: 279 L (range: 125 L to 473 L).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Propiverine: 90% to 95%; propiverine-N-oxide (main metabolite): 60%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive via hepatic and intestinal enzymes, primarily by oxidation of piperidyl-N and mediated by CYP3A4 and flavin-monooxygenases (FMO) 1 and 3; main metabolite propiverine-N-oxide.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Large first-pass effect; Immediate release: 53.3% (increased with high-fat meal); Modified release: 59.5% to 60.8% ± 17.3% to 23.3%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Immediate release: 11.4 hours (range: 7.4 to 17.7 hours); Modified release: 14.2 to 16.3 hours (range: 10.8 to 19.2 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Immediate release: ~2 hours; Modified release: ~10 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60%, &lt;1% unchanged); Feces (21%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22786649"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">He er shu | Hua ke | Pei ning</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm | Mictonorm uno | Prodrom | Pronenz | Propimedac | Propiver | Propiverin 1A Pharma | Propiverin AL | Propiverin aristo | Propiverin HCl Stada | Propiverin Hexal | Propiverin Sandoz | Propiverin uropharm</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Urimagictam</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Detrunorm</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Balrer | Benzfore | Bifolvelin | Bup 4 taiho | Bup-4 | Bupverine | Mictonorm | Noraguard | Penifor | Pollarine | Propive | Propive hexal | Propiverine HCL | Propiverine Hcl Fuji | Propiverine Hcl Kobayashi | Propiverine Hcl Kowa | Propiverine Hcl Sawai | Propiverine Hcl Tatumi | Propiverine Nihon | Urecure | Urilosin | Uronaverine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bearverine | Bieuverin | Bpro | Bproverin | Bup-4 | Bupro | Claverin | Cureverin | Daewoongbio propiverine | Ditroberin | Ditruverin | Eurodel | Everin | Gloverin | Hupiverine | Mictonorm | Newwelbi | Nexverine | Piverine | Poverin | Priverin | Prop | Propiberin | Propiverine | Prorine | Prositol | Prove | Proverin | Provine | Reyon propiverine | Samsung propiverine | Uberin | Upiverine | Urinel | Urinna | Urobin | Urocon | Urocone | Urofix | Urona | Uropro | Urostop | Uroverine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm uno</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Propiverine</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm | Mictonorm XL</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mictonorm</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Eccury | Mictonorm</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Urotrol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Detrunorm</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/propiverine-united-states-not-available-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mictoryl, Mictoryl Pediatric (propiverine) [product monograph]. Blainville, Quebec, Canada: Duchesnay Inc; January 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 114006 Version 102.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
